» Articles » PMID: 34407760

RAAV9-mediated Supplementation of MiR-29b Improve Angiotensin-II Induced Renal Fibrosis in Mice

Overview
Journal Mol Med
Publisher Biomed Central
Date 2021 Aug 19
PMID 34407760
Citations 4
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Renin-angiotensin-aldosterone system activation is the critical factor in renal remodeling and dysfunction. Our previous study suggested that miR-29b may attenuate AngII-induced renal intestinal fibrosis in vitro. In the present study, we aimed to determine whether recombinant rAAV9-mediated miR-29b delivery protects against AngII-induced renal fibrosis and dysfunction.

Method: Mice were treated with AngII via osmotic mini-pumps, or phosphate-buffered saline. rAAV9 vectors were produced using the rBac-based system in SF9 cells. rAAV9-miR-29b or rAAV9-control-miR was injected into the kidneys of mice subjected to the model of AngII infusion. The role of miR-29b in renal fibrosis was assessed using quantitative polymerase chain reaction, western blot, and histology.

Results: In AngII-induced fibrotic kidney tissue, miR-29b expression was downregulated. rAAV9-miR-29b delivery significantly reversed renal injury as indicated by decreased serum creatinine and injury related gene expression in AngII-infused mice. Regarding organ remodeling, tubulointerstitial fibrosis and deposition of extracellular matrix components such as collagen type I and type III were significantly decreased in renal tissue from mice delivered rAAV9-miR-29b.

Conclusion: Our results demonstrate great potential for use of rAAV9 as an applicable vector for delivery of miR-29b as an antifibrogenic factor for treatment of tubulointerstitial fibrosis-induced renal injury.

Citing Articles

Salidroside Pre-Treatment Inhibits Hypertensive Renal Injury and Fibrosis Through Inhibiting Wnt/β-Catenin Pathway.

Zhu J, Li L, Luan Y, Zhang Z, Wang Y, Xu Z Dose Response. 2024; 22(4):15593258241298045.

PMID: 39506979 PMC: 11539081. DOI: 10.1177/15593258241298045.


Interaction of estradiol and renin-angiotensin system with microRNAs-21 and -29 in renal fibrosis: focus on TGF-β/smad signaling pathway.

Rajabi S, Saberi S, Najafipour H, Askaripour M, Rajizadeh M, Shahraki S Mol Biol Rep. 2024; 51(1):137.

PMID: 38236310 DOI: 10.1007/s11033-023-09127-4.


Association between Circulating MicroRNAs (miR-21-5p, miR-20a-5p, miR-29b-3p, miR-126-3p and miR-101-3p) and Chronic Allograft Dysfunction in Renal Transplant Recipients.

Chen Y, Hsu C, Tsai S, Chen C Int J Mol Sci. 2022; 23(20).

PMID: 36293110 PMC: 9603156. DOI: 10.3390/ijms232012253.


Ameliorates Renal Hypertensive Injury and Fibrosis Through the Regulation of SIRT1-Mediated Autophagy.

Cai Y, Feng Z, Jia Q, Guo J, Zhang P, Zhao Q Front Pharmacol. 2022; 12:801094.

PMID: 35222012 PMC: 8866973. DOI: 10.3389/fphar.2021.801094.

References
1.
Kriegel A, Liu Y, Fang Y, Ding X, Liang M . The miR-29 family: genomics, cell biology, and relevance to renal and cardiovascular injury. Physiol Genomics. 2012; 44(4):237-44. PMC: 3289120. DOI: 10.1152/physiolgenomics.00141.2011. View

2.
Almeida L, Tofteng S, Madsen K, Jensen B . Role of the renin-angiotensin system in kidney development and programming of adult blood pressure. Clin Sci (Lond). 2020; 134(6):641-656. DOI: 10.1042/CS20190765. View

3.
DuPont J, McCurley A, Davel A, McCarthy J, Bender S, Hong K . Vascular mineralocorticoid receptor regulates microRNA-155 to promote vasoconstriction and rising blood pressure with aging. JCI Insight. 2016; 1(14):e88942. PMC: 5033871. DOI: 10.1172/jci.insight.88942. View

4.
Xiong M, Jiang L, Zhou Y, Qiu W, Fang L, Tan R . The miR-200 family regulates TGF-β1-induced renal tubular epithelial to mesenchymal transition through Smad pathway by targeting ZEB1 and ZEB2 expression. Am J Physiol Renal Physiol. 2011; 302(3):F369-79. DOI: 10.1152/ajprenal.00268.2011. View

5.
Pan J, Zhang J, Zhang X, Zhou X, Lu S, Huang X . Role of microRNA-29b in angiotensin II-induced epithelial-mesenchymal transition in renal tubular epithelial cells. Int J Mol Med. 2014; 34(5):1381-7. DOI: 10.3892/ijmm.2014.1935. View